glp 1 agonist eli lilly Orforglipron: Lilly's New Oral GLP-1 Weight-loss Pill ADA 2026 confirmed what many

Preclinical investigations have shown that these agents downregulate proprotein convertase subtilisin/kexin type 9 (PCSK9) expression, upregulate low-density lipoprotein receptor (LDLR) levels, and suppress postprandial secretion of triglycerides and chylomicrons (87, 88)

Second, improvements in IR and glycaemic indices are most apparent in higher-burden phenotypes, particularly in women with impaired glucose tolerance/prediabetes or related metabolic comorbidities, where changes in HOMA-IR, fasting glucose and OGTT profiles are more pronounced and may plausibly reduce periconception metabolic risk

In this regard, we recommend using a composite endpoint of both the number of daily bowel movements and the number of stools of type 6 or 7 on the Bristol stool form scale

TrustLoop Partnership We test, you test, we reward